Semax: BDNF, Attention and the Russian Neuropeptide Lineage

Semax is a heptapeptide derived from a fragment of ACTH, modified to remove the hormonal activity and keep the effects on the central nervous system. It is registered as a medicine in Russia for certain indications, which puts any discussion of semax nootropic benefits in an unusual position. No trials exist that meet the methodological standards normally applied in Europe or the United States.

From ACTH to a heptapeptide

ACTH, adrenocorticotropic hormone, is a 39-amino-acid molecule whose known function is to stimulate the adrenal cortex to produce cortisol.

Some of its fragments were observed to retain effects on the central nervous system without hormonal activity: effects on attention, memory and learning.

Semax was developed from the ACTH(4-10) fragment by adding three amino acids (proline, glycine, proline) at the C-terminal end. That modification serves two purposes:

1. It increases resistance to degradation by peptidases.
2. It removes corticotropic activity: it does not stimulate cortisol production.

Hence the description of the compound as "the central effects of ACTH without its hormonal effects."

What BDNF is and why it carries so much weight

Brain-derived neurotrophic factor is a protein involved in neuronal survival, in the growth of connections and in synaptic plasticity, the capacity of connections to strengthen or weaken with experience, which is the cellular basis of learning.

Its levels are associated with cognitive function, with mood and with the response to exercise, one of the stimuli that raise it most consistently.

The effect attributed to Semax is an increase in BDNF expression. And here the usual warning is needed, because this field forgets it especially fast: BDNF is a marker. Its elevation is associated with cognitive function; that raising it pharmacologically improves cognition is a different claim, one that requires measuring cognition, not BDNF. This is the gap between marker and outcome.

Clinical use in Russia and the indications it covers

Semax is registered as a medicine in Russia. Its registered indications include contexts of cerebral circulatory disorders and certain cognitive impairments, and it is used within the country's health system.

What that means, precisely:

It means a national regulatory authority reviewed a dossier and authorized marketing. That is more than most compounds in this catalog can say.

It does not mean that evidence exists under the standards the FDA or the EMA apply. Requirements for design, sample size, prior registration and publication differ between regulatory frameworks, and that difference is material.

Presenting the Russian registration as equivalent to an FDA or EMA approval would be misleading. Presenting it as if it did not exist would be misleading too.

Intranasal versus subcutaneous

The intranasal route is the usual form of administration in Russian use, and there is a reason behind it.

The nasal mucosa offers a route that has been described as able to facilitate access to the central nervous system along pathways associated with the olfactory and trigeminal nerves, partially bypassing the blood-brain barrier.

It is a route recognized in pharmaceutical research and grounded in anatomy. That said: how much molecule actually reaches brain tissue by that route, and in what proportion to the administered dose, is a question that depends on the compound, and for Semax it is not quantified in accessible literature.

The problem of access to the literature

This section explains why forming a solid opinion about this compound is so difficult. Anyone weighing semax nootropic benefits hits this wall first.

Much of the research is published in Russian, in Russian journals, with two practical consequences:

Access barrier. Many papers are not indexed in the usual international databases and are not available in translation.

Assessment is difficult. Without the full text, design, randomization, blinding and analysis cannot be evaluated. An outside reader cannot judge the quality of what they cannot read.

The honest conclusion is an uncomfortable one: the evidence cannot be called solid, and it cannot be called weak either. What can be said is that it is not assessable from outside with the usual tools, and that is a different situation from an absence of evidence.

What is known about tolerance and prolonged use

Little, and that is worth saying plainly.

The tolerability profile described in Russian clinical use is presented as favorable, with adverse effects that are infrequent and mostly related to the intranasal route (local irritation).

What is not characterized in accessible literature: what happens with prolonged use, whether tolerance to the effect develops, and what the medium- and long-term safety profile looks like outside the registered indications.

Batch analytical data are in its technical sheet. The comparison with its sibling compound is in Semax versus Selank.

What the evidence does not settle

• Efficacy under Western standards: no trials meet them.
• Human pharmacokinetics by the intranasal route: not quantified in accessible literature.
• Effect on cognition measured with validated instruments in a healthy population.
• Prolonged use: no data.
• Whether the rise in BDNF translates into anything functional: not demonstrated.

This content is strictly educational and does not constitute medical advice, diagnosis or a therapeutic recommendation. The compounds mentioned are research products (Research Use Only) and are not approved by INVIMA, FDA, EMA or ANSM for therapeutic use in humans. Any health-related decision should be made with a licensed medical professional.